Compare KAI & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KAI | AAPG |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | N/A | 2025 |
| Metric | KAI | AAPG |
|---|---|---|
| Price | $289.69 | $30.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $340.00 | $48.50 |
| AVG Volume (30 Days) | ★ 143.8K | 4.1K |
| Earning Date | 10-28-2025 | 11-19-2025 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.65 | N/A |
| Revenue | ★ $1,024,074,000.00 | $54,524,554.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.56 | $368.64 |
| P/E Ratio | $33.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $244.87 | $16.50 |
| 52 Week High | $409.73 | $48.45 |
| Indicator | KAI | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 42.17 |
| Support Level | $276.80 | $28.50 |
| Resistance Level | $300.44 | $32.96 |
| Average True Range (ATR) | 9.69 | 0.70 |
| MACD | 2.66 | -0.05 |
| Stochastic Oscillator | 72.75 | 40.31 |
Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.